These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23396856)

  • 21. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
    Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
    Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
    Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
    McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
    J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
    Charpentier C; Joly V; Larrouy L; Fagard C; Visseaux B; de Verdière NC; Raffi F; Yeni P; Descamps D;
    J Antimicrob Chemother; 2013 Mar; 68(3):690-6. PubMed ID: 23152480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.
    Carmona R; Pérez-Alvarez L; Muñoz M; Casado G; Delgado E; Sierra M; Thomson M; Vega Y; Vázquez de Parga E; Contreras G; Medrano L; Nájera R
    J Clin Virol; 2005 Mar; 32(3):248-53. PubMed ID: 15722032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
    Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
    J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of polyanion-resistance on HIV-1 infection.
    Bobardt MD; Armand-Ugón M; Clotet I; Zhang Z; David G; Este JA; Gallay PA
    Virology; 2004 Aug; 325(2):389-98. PubMed ID: 15246277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
    Soulié C; Malet I; Lambert-Niclot S; Tubiana R; Thévenin M; Simon A; Murphy R; Katlama C; Calvez V; Marcelin AG
    AIDS; 2008 Oct; 22(16):2212-4. PubMed ID: 18832886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
    Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
    J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248).
    Regueiro-Ren A; Xue QM; Swidorski JJ; Gong YF; Mathew M; Parker DD; Yang Z; Eggers B; D'Arienzo C; Sun Y; Malinowski J; Gao Q; Wu D; Langley DR; Colonno RJ; Chien C; Grasela DM; Zheng M; Lin PF; Meanwell NA; Kadow JF
    J Med Chem; 2013 Feb; 56(4):1656-69. PubMed ID: 23360431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of X4/DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission.
    Briz V; García D; Méndez-Lagares G; Ruiz-Mateos E; de Mulder M; Moreno-Pérez D; Navarro ML; León-Leal JA; de José MI; Ramos JT; Mellado MJ; González-Tomé MI; Leal M; Muñoz-Fernández MA
    Pediatr Infect Dis J; 2012 Oct; 31(10):1048-52. PubMed ID: 22828644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.
    Férir G; Hänchen A; François KO; Hoorelbeke B; Huskens D; Dettner F; Süssmuth RD; Schols D
    Virology; 2012 Nov; 433(2):308-19. PubMed ID: 22959895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
    Hachiya A; Aizawa-Matsuoka S; Tanaka M; Takahashi Y; Ida S; Gatanaga H; Hirabayashi Y; Kojima A; Tatsumi M; Oka S
    Antimicrob Agents Chemother; 2001 Feb; 45(2):495-501. PubMed ID: 11158746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study.
    Frange P; Galimand J; Goujard C; Deveau C; Ghosn J; Rouzioux C; Meyer L; Chaix ML
    J Antimicrob Chemother; 2009 Jul; 64(1):135-41. PubMed ID: 19411680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
    Wang HG; Williams RE; Lin PF
    Curr Pharm Des; 2004; 10(15):1785-93. PubMed ID: 15180540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.